Sooi K, Tan TZ, Kim JW, Lee JY, et al. A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients. Br J Cancer 2025 Jul 22. doi: 10.1038/s41416-025-03090.
PMID: 40696160